GLPwatch
Papers (9189)
Page 69 of 154, ranked by citation count.
- Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
- The efficacy and safety of liraglutide.
- Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake.
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
- Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics.
- Why are we still in need for novel anti-obesity medications?
- Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus.
- Semaglutide treatment for children with obesity: an observational study.
- Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
- Functional association of the N-terminal residues with the central region in glucagon-related peptides.
- Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.
- Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function.
- Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.
- Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.
- Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
- Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.
- Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
- Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14.
- Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.
- Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
- Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.
- Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
- Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
- Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
- Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1.
- Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
- Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.
- Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.
- A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
- Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
- A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.
- Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
- Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
- Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
- Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
- Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.
- Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.
- LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION.
- Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
- Liraglutide in oral antidiabetic drug combination therapy.
- Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
- Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
- Liraglutide Improves Endothelial Function via the mTOR Signaling Pathway.
- Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
- Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish.
- Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.
- GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.
- A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
- Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.
- Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
- Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.
- A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
- Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
- Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
- Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
- Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats.
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?